Skip to main content
Premium Trial:

Request an Annual Quote

ERS Genomics Licenses CRISPR/Cas9 IP to Lepton Pharmaceuticals

NEW YORK — ERS Genomics said on Tuesday that it has nonexclusively licensed its CRISPR/Cas9 patent portfolio to Lepton Pharmaceuticals for undisclosed applications.

Financial and other terms of the deal were not disclosed.

Lepton, based in Israel, is developing a technology that engineers microRNAs to improve the efficiency and longevity of cells used in cell-based cancer immunotherapies.

Dublin, Ireland-based ERS was founded to provide access to CRISPR-Cas9 patents held by Emmanuelle Charpentier. The IP is shared with Jennifer Doudna and the University of California, as well as with the University of Vienna.

Last month, ERS nonexclusively licensed its technology to Cytosurge.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.